Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
Leigh MacConell, Carl Brown, Kate Gurney, Jenny HanAmylin Pharmaceuticals, Inc. San Diego, CA, USABackground: Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the safety prof...
Guardado en:
Autores principales: | Gurney K, Brown C, MacConell L, Han J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd89b9880170477489a05b4961494654 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell L, et al.
Publicado: (2015) -
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell L, et al.
Publicado: (2013) -
Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
por: Anichini R, et al.
Publicado: (2013) -
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
por: Ostenson CG, et al.
Publicado: (2013) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)